966 related articles for article (PubMed ID: 27343720)
1. Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation-Results from a Single-Center Observational Study.
Grube M; Holler E; Weber D; Holler B; Herr W; Wolff D
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1781-1791. PubMed ID: 27343720
[TBL] [Abstract][Full Text] [Related]
2. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia.
Gratwohl A; Brand R; Apperley J; Biezen Av Av; Bandini G; Devergie A; Schattenberg A; Frassoni F; Guglielmi C; Iacobelli S; Michallet M; Kolb HJ; Ruutu T; Niederwieser D;
Blood; 2002 Dec; 100(12):3877-86. PubMed ID: 12433695
[TBL] [Abstract][Full Text] [Related]
3. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
4. Ex Vivo CD34
Barba P; Hilden P; Devlin SM; Maloy M; Dierov D; Nieves J; Garrett MD; Sogani J; Cho C; Barker JN; Kernan NA; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Prockop S; Sauter C; Tamari R; van den Brink MR; Avecilla ST; Meagher R; O'Reilly RJ; Goldberg JD; Young JW; Giralt S; Perales MA; Ponce DM
Biol Blood Marrow Transplant; 2017 Mar; 23(3):452-458. PubMed ID: 28017734
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and risk of chronic graft-versus-host disease of liver in allogeneic hematopoietic stem cell transplant recipients.
Chen CT; Liu CY; Yu YB; Liu CJ; Hsiao LT; Gau JP; Chiou TJ; Liu JH; Liu YC
PLoS One; 2017; 12(9):e0185210. PubMed ID: 28934311
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after Allogeneic Hematopoietic Stem Cell Transplantation.
Inagaki J; Moritake H; Nishikawa T; Hyakuna N; Okada M; Suenobu S; Nagai K; Honda Y; Shimomura M; Fukano R; Noguchi M; Kurauchi K; Tanioka S; Okamura J
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1973-80. PubMed ID: 26234723
[TBL] [Abstract][Full Text] [Related]
7. [Effect of graft-versus-host disease on relapse and survival in 100 patients after allogeneic hematopoietic stem cell transplantation].
Deng XR; Ren HY; Cen XN; Wang LH; Liang ZY; Wang WS; Qiu ZX; Ou JP; Xu WL; Wang MJ; Li Y; Yin Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Aug; 17(4):994-8. PubMed ID: 19698246
[TBL] [Abstract][Full Text] [Related]
8. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival.
Moon JH; Sohn SK; Lambie A; Ellis L; Hamad N; Uhm J; Gupta V; Lipton JH; Messner HA; Kuruvilla J; Kim D
Biol Blood Marrow Transplant; 2014 Apr; 20(4):556-63. PubMed ID: 24447907
[TBL] [Abstract][Full Text] [Related]
9. [Impact of graft versus host disease on outcome of allogeneic peripherial blood stem cell transplantation for leukemia].
Li M; Zhang W; Wang J; Song X; Yang J; Ni X; Yang D; Chen L; Chen J; Hu X; Gao L; Qiu H; Zhou H; Cheng H
Zhonghua Xue Ye Xue Za Zhi; 2014 May; 35(5):428-33. PubMed ID: 24857214
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation.
Pavletic SZ; Smith LM; Bishop MR; Lynch JC; Tarantolo SR; Vose JM; Bierman PJ; Hadi A; Armitage JO; Kessinger A
Am J Hematol; 2005 Apr; 78(4):265-74. PubMed ID: 15795914
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for chronic graft-versus-host disease after anti-thymocyte globulin-based haploidentical hematopoietic stem cell transplantation in acute myeloid leukemia.
Lv M; Zhang X; Xu L; Wang Y; Yan C; Chen H; Chen Y; Han W; Wang F; Wang J; Liu K; Huang X; Mo X
Front Med; 2019 Dec; 13(6):667-679. PubMed ID: 31512033
[TBL] [Abstract][Full Text] [Related]
12. Clinical separation of cGvHD and GvL and better GvHD-free/relapse-free survival (GRFS) after unrelated cord blood transplantation for AML.
Zheng CC; Zhu XY; Tang BL; Zhang XH; Zhang L; Geng LQ; Liu HL; Sun ZM
Bone Marrow Transplant; 2017 Jan; 52(1):88-94. PubMed ID: 27376453
[TBL] [Abstract][Full Text] [Related]
13. Risk factors associated with liver injury and impact of liver injury on transplantation-related mortality in pediatric recipients of allogeneic hematopoietic stem cell transplantation.
Radhakrishnan K; Bishop J; Jin Z; Kothari K; Bhatia M; George D; Garvin JH; Martinez M; Ovchinsky N; Lobritto S; Elsayed Y; Satwani P
Biol Blood Marrow Transplant; 2013 Jun; 19(6):912-7. PubMed ID: 23467127
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic peripheral blood stem cell transplantation significantly increases risk of chronic graft-versus-host disease of lung compared with bone marrow transplantation.
Alam N; Marras TK; Atenafu EG; Gupta V; Kuruvilla J; Lipton JH; Messner HA; Kim DD
Biol Blood Marrow Transplant; 2012 Dec; 18(12):1905-10. PubMed ID: 22835425
[TBL] [Abstract][Full Text] [Related]
15. Mismatch on glutathione S-transferase T1 increases the risk of graft-versus-host disease and mortality after allogeneic stem cell transplantation.
Martínez-Bravo MJ; Calderón-Cabrera C; Márquez-Malaver FJ; Rodríguez N; Guijarro M; Espigado I; Núñez-Roldán A; Pérez-Simón JA; Aguilera I
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1356-62. PubMed ID: 24844856
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the national institutes health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy.
Pérez-Simón JA; Encinas C; Silva F; Arcos MJ; Díez-Campelo M; Sánchez-Guijo FM; Colado E; Martín J; Vazquez L; Del Cañizo C; Caballero D; San Miguel J
Biol Blood Marrow Transplant; 2008 Oct; 14(10):1163-1171. PubMed ID: 18804047
[TBL] [Abstract][Full Text] [Related]
17. Graft-versus-tumor effect according to type of graft-versus-host disease defined by National Institutes of Health consensus criteria and associated outcomes.
Cho BS; Lee SE; Song HH; Lee JH; Yahng SA; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW
Biol Blood Marrow Transplant; 2012 Jul; 18(7):1136-43. PubMed ID: 22261380
[TBL] [Abstract][Full Text] [Related]
18. Reduced intensity conditioning increases risk of severe cGVHD: identification of risk factors for cGVHD in a multicenter setting.
Afram G; Simón JAP; Remberger M; Caballero-Velázquez T; Martino R; Piñana JL; Ringden O; Esquirol A; Lopez-Corral L; Garcia I; López-Godino O; Sierra J; Caballero D; Ljungman P; Vazquez L; Hägglund H
Med Oncol; 2018 Apr; 35(6):79. PubMed ID: 29696461
[TBL] [Abstract][Full Text] [Related]
19. Risk-factor analysis for predicting progressive- or quiescent-type chronic graft-versus-host disease in a patient cohort with a history of acute graft-versus-host disease after allogeneic stem cell transplantation.
Sohn SK; Kim DH; Baek JH; Kim JG; Lee KB; Lee KH; Lee JH; Choi SJ; Lee JH; Shin IH
Bone Marrow Transplant; 2006 Apr; 37(7):699-708. PubMed ID: 16501588
[TBL] [Abstract][Full Text] [Related]
20. Chronic graft-versus-host disease of the kidney in patients with allogenic hematopoietic stem cell transplant.
Fraile P; Vazquez L; Caballero D; Garcia-Cosmes P; López L; San Miguel J; Tabernero JM
Eur J Haematol; 2013 Aug; 91(2):129-34. PubMed ID: 23710658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
